The efficacy of omalizumab therapy in chronic spontaneous urticaria: A retrospective analysis
Journal Title: Türkderm - Deri Hastalıkları ve Frengi Arşivi - Year 2019, Vol 53, Issue 2
Abstract
Background and Design: Omalizumab is recombinant humanized monoclonal antibody that binds to immunoglobulin E (IgE). It inhibits the activation of IgE by binding to the effector cell, thereby inhibiting the release of cellular mediators. Omalizumab is indicated in H1- antihistamine-resistant chronic spontaneous urticaria (CSU) cases and data on successful use in CSU is increasing. The aim of this study was to evaluate the efficacy and possible side effects of omalizumab, the period from the discontinuation of treatment to the relapse of symptoms, and the clinical and demographic characteristics of patients with refractory CSU. Materials and Methods: We retrospectively evaluated the data of 130 patients with refractory CSU who received subcutaneous 300 mg/ month omalizumab therapy in our clinic. Results: Complete remission was achieved in 77.8% of the patients. Of the 80 patients who discontinued therapy due to remission, 55% had relapses within 2 months to 1 year. It was observed that the efficacy of the drug was not lost and the efficacy did not change in the patients who started the treatment again. Six percent of the patients did not respond to treatment. Clinical improvement was found to be independent of age, gender, presence of angioedema, high thyroid autoantibody levels and disease duration. No serious side effects were found in the patients. Conclusion: In patients with refractory CSU, omalizumab is an effective and safe treatment option.
Authors and Affiliations
Meltem Turkmen, Melis Çoban, Sinan Dogan, Fatma Uygur, İbrahim Hakkı Soylu
Keywords
Related Articles
- EP ID EP605880
- DOI 10.4274/turkderm.galenos.2018.78476
- Views 79
- Downloads 0
Evaluation of psoriasis patients with a rheumatologic questionnaire efficiently aids in early detection of psoriatic arthritis
Background and Design: Psoriatic arthritis (PsA), enthesitis and/or soft tissue swelling accompany psoriasis in 6-30% of all psoriatic patients. Early recognition of PsA is crucial since it is a serious disabling comorbi...
Factors affecting the development of scar formation in abdominal surgery performed for gynecologic and obstetric conditions
Background and Design: The aim of this study is to investigate whether there can be a difference in types of scars developed on the same type of incisions due to cesarean section or benign gynecologic operations, and to...
SAPHO syndrome associated with acne fulminans in an adolescent patient
Here, we present an adolescence patient of SAPHO syndrome successfully treated with etanercept and isotretinoin.
Perforating pilomatrixoma showing atypical presentation: A rare clinical variant
Pilomatrixoma, also known as calcifying epithelioma of Malherbe, is a rare benign skin tumor arising from hair follicle stem cells. The most common localization is the head and neck region. Female/male ratio is 3/2. It s...
Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature
Ustekinumab is a Food and Drug Administration-approved (2009) novel treatment for psoriasis patients. This anti-interleukin-12/23p40 monoclonal antibody is effective in the treatment of plaque psoriasis and psoriatic art...